Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine and Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Pleasanton, CA and Tokyo, Japan, June 6th, 2019. Astex Pharmaceuticals, Inc. a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials

Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
Conditions:   Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory High Risk Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia Interventions:   Drug: Decitabine;   Biological: Pembrolizumab Sponsors:   City of Hope Medical C...
Source: ClinicalTrials.gov - May 31, 2019 Category: Research Source Type: clinical trials

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   IDH1 NP_005887.2:p.R132C;   IDH1 NP_005887.2:p.R132G;   IDH1 NP_005887.2:p.R132H;   IDH1 NP_005887.2:p.R132L;   IDH1 NP_005887.2:p.R132S;   IDH2 NP_002159.2:p.R140X;   IDH2 NP_002159.2:p.R172G;   IDH2 NP_002 159.2:p.R172K;   IDH2 NP_002159.2:p.R172M;   IDH2 NP_002159.2:p.R172W;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   T...
Source: ClinicalTrials.gov - May 17, 2019 Category: Research Source Type: clinical trials

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   IDH1 NP_005887.2:p.R132C;   IDH1 NP_005887.2:p.R132G;   IDH1 NP_005887.2:p.R132H;   IDH1 NP_005887.2:p.R132L;   IDH1 NP_005887.2:p.R132S;   IDH1 NP_005887.2:p.R132V;   IDH2 NP_002159.2:p.R140L;   IDH2 NP_002 159.2:p.R140Q;   IDH2 NP_002159.2:p.R140W;   IDH2 NP_002159.2:p.R140X;   IDH2 NP_002159.2:p.R172G;   IDH2 NP_002159.2:p.R172K;   IDH2 NP_002159.2:p.R172M;   IDH2 NP_002159.2:p.R172S;   ...
Source: ClinicalTrials.gov - May 17, 2019 Category: Research Source Type: clinical trials

A Phase II Efficacy and Safety Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Condition:   Myelodysplastic Syndromes Interventions:   Drug: MBG453;   Drug: Placebo;   Drug: Hypomethylating agents Sponsor:   Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 13, 2019 Category: Research Source Type: clinical trials

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Condition:   Myelodysplastic Syndromes Interventions:   Drug: MBG453;   Drug: Placebo;   Drug: Hypomethylating agents Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 13, 2019 Category: Research Source Type: clinical trials

A Phase II Efficacy and Safety Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Condition:   Myelodysplastic Syndromes Interventions:   Drug: MBG453;   Drug: Placebo;   Drug: Hypomethylating agents Sponsor:   Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 13, 2019 Category: Research Source Type: clinical trials

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Conditions:   Acute Myeloid Leukemia (AML);   High-risk Myelodysplastic Syndrome (MDS) Interventions:   Drug: HDM201;   Biological: MBG453;   Drug: Venetoclax Sponsor:   Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 7, 2019 Category: Research Source Type: clinical trials

ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes Intervention:   Drug: ONC201 Sponsor:   Vijaya Bhatt Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2019 Category: Research Source Type: clinical trials